Abstract:
Background:
Jump to section
Background:
Design and methods:
Results:
Conclusions:
Introduction
Methods
Results
Discussion
Conclusions
Transparency
Several studies that evaluated achieving lipid goals have demonstrated an undertreatment of dyslipidemia. We evaluated the use and efficacy of lipid-lowering agents (LLAs) in reducing low-density lipoprotein cholesterol (LDL-C) to recommended levels in the Levant region.
Design and methods:
Jump to section
Background:
Design and methods:
Results:
Conclusions:
Introduction
Methods
Results
Discussion
Conclusions
Transparency
A multi-center, cross-sectional survey enrolled 1002 dyslipidemic patients (August 2010 – January 2011) on LLAs for ≥3 months. Collection of data and blood samples was done over one visit. Physicians and patients filled out questionnaires pertaining to dyslipidemia diagnosis and treatment. LDL-C target levels were defined according to international guidelines.
Results:
Jump to section
Background:
Design and methods:
Results:
Conclusions:
Introduction
Methods
Results
Discussion
Conclusions
Transparency
The full analysis set included 992 patients. Mean age was 58.0 ± 11.6 years (41% women, 65.7% diabetics and 51.5% had history of coronary heart disease). LLAs were prescribed for primary prevention or secondary prevention or familial hypercholesterolemia in 45.8% and 52.8% and 1.4% of patients; respectively. Overall, 64.0% and 56.8% of the patients attained their LDL-C goal recommended by the NCEP ATP III and TJETF guidelines, respectively. According to the 2004 NCEP ATP III updated guidelines, about 24.8% of the very high risk group attained their LDL goal of ≤70 mg/dL. Smoking, diabetes, metabolic syndrome, history of cardiovascular disease, increased waist circumference, and elevated pre-treatment LDL-C level were all associated with not reaching LDL-C goals.
Conclusions:
Jump to section
Background:
Design and methods:
Results:
Conclusions:
Introduction
Methods
Results
Discussion
Conclusions
Transparency
Although the study cohort was a relatively high risk group and might not be representative of the general population, we found that about 60% of enrolled individuals achieved the LDL-C treatment goals and 24.8% of the very high risk group achieved the recommended LDL-C targets of ≤70 mg/dl; national strategies and aggressive awareness campaigns to effectively control lipid levels to recommended target levels, especially in the high risk groups, are urgently needed.
Citation:
Hammoudeh, A. J., Echtay, A., Ghanem, G. Y., & Haddad, J. (2014). Achieving low-density lipoprotein cholesterol treatment goals among dyslipidemic individuals in the Levant: the CEntralized Pan-Levant survey on tHE Undertreatment of hypercholeSterolemia (CEPHEUS) study. Current medical research and opinion, 30(10), 1957-1965.